Our strategic approach is to apply advanced formulation and delivery technologies to produce effective drugs that are packaged in ready-to-use, room temperature stable formats, i.e. no diluent, no mixing and no needles. The simplification in storage and drug administration will benefit the patients and provide a strong purchasing incentive for the healthcare providers.

Panaecin^TM and Aerucin^TM will be produced as refrigerator stable liquid formulations ready for parenteral injection. For applications where direct inhalation to the lung is required, these drugs can be produced as room temperature stable, spray dried powders with the aerosol properties amendable for deep lung delivery using cost effective commercially available dry powder inhalers. Rotavax will be produced as a room temperature stable quick dissolving wafer for convenient delivery to the oral mucosa.

Our technology portfolio comprise of formulation stabilization technology and delivery technologies in the form of inhalable powders for lung delivery and quick dissolving thin film for oral delivery of vaccines.